Immutep Limited - American Depositary Shares (OQ:IMMP)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Apr 18, 2024 08:00 am ET

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with the Centre...

Apr 17, 2024 08:00 am ET

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Mar 05, 2024 08:00 am ET

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first...

Jan 30, 2024 08:00 am ET

Immutep Quarterly Activities Report Q2 FY24

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product...

Jan 04, 2024 08:00 am ET

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Dec 21, 2023 08:00 am ET

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the...

Dec 07, 2023 08:00 am ET

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~...

Nov 22, 2023 08:00 am ET

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 09, 2023 08:00 am ET

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 06, 2023 08:00 am ET

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 03, 2023 12:00 pm ET

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 02, 2023 08:00 am ET

Immutep to Participate in November Investor Events

Oct 31, 2023 08:00 am ET

Immutep Quarterly Activities Report Q1 FY24

Phase IIb TACTI-003 trial recruitment progressing and expected to be complete in November 20231L NSCLC - Preparations ongoing to commence Phase III TACTI-004 registrational trial in CY2024Metastatic breast cancer (MBC) - Patient recruitment ongoing...

Oct 25, 2023 08:00 am ET

Immutep receives ~A$1.13 million R&D Tax Incentive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of...

Oct 24, 2023 08:00 am ET

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer continuesStrong 71.4% Overall Response Rate, 90.5%...

Oct 23, 2023 08:00 am ET

Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached...

Oct 16, 2023 08:00 am ET

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 03, 2023 08:00 am ET

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation...

Sep 21, 2023 08:00 am ET

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Sep 05, 2023 09:00 am ET

Immutep to Participate in September Investor Conferences

Aug 01, 2023 08:00 am ET

Immutep Receives Positive Scientific Advice from European Medicines Agency

Jul 31, 2023 08:00 am ET

Immutep Quarterly Activities Report Q4 FY23

Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC)TACTI-003 Phase IIb – Randomised study in...

Jul 31, 2023 08:00 am ET

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Jul 28, 2023 08:00 am ET

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Jun 27, 2023 08:00 am ET

Immutep Completes A$80 Million Capital Raise

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the successful completion of an A$80 million...

Jun 27, 2023 08:00 am ET

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled “Combined Preparations...

Jun 20, 2023 08:00 am ET

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

Jun 07, 2023 08:00 am ET

Immutep to Participate at the Jefferies Healthcare Conference

Jun 05, 2023 08:00 am ET

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase IIPromising efficacy in patients with...

Jun 02, 2023 08:00 am ET

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an institutional placement (Placement) and the institutional component (Institutional Entitlement Offer)...

May 29, 2023 08:00 am ET

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

May 26, 2023 08:00 am ET

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces data from Part C of its TACTI-002 Phase II trial...

May 25, 2023 08:00 am ET

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

May 24, 2023 08:00 am ET

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

May 17, 2023 08:00 am ET

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002 trialInitial median Overall Survival of 25...

May 16, 2023 08:00 am ET

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

May 09, 2023 08:00 am ET

Immutep to Participate in the JMP Securities Life Sciences Conference

May 02, 2023 08:00 am ET

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co,...

May 01, 2023 08:00 am ET

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (“PEI”),...

Apr 27, 2023 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product...

Apr 26, 2023 10:00 am ET

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

Apr 26, 2023 08:00 am ET

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical...

Apr 17, 2023 09:00 am ET

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

Mar 31, 2023 08:00 am ET

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line...

Mar 30, 2023 08:00 am ET

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

Mar 23, 2023 08:00 am ET

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that new data evaluating eftilagimod alpha in combination with pembrolizumab...

Mar 14, 2023 08:00 am ET

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

Feb 06, 2023 08:00 am ET

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the investigator-initiated INSIGHT-003 trial...

Jan 30, 2023 08:00 am ET

Immutep Quarterly Activities Report

002 trial combining efti and pembrolizumab, showcased at SITC 2022 press briefingSuccessful meeting with FDA for efti in metastatic breast cancer (MBC) and agreement for integrated Phase II/III trial design with expanded patient population to...

Jan 04, 2023 08:00 am ET

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

Dec 23, 2022 08:00 am ET

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

Dec 08, 2022 08:00 am ET

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

Dec 06, 2022 08:00 am ET

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has...

Dec 02, 2022 08:00 am ET

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Nov 29, 2022 08:00 am ET

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, an

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial...

Nov 14, 2022 08:00 am ET

Immutep Receives Australian R&D Tax Incentive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in...

Nov 10, 2022 11:10 am ET

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across all PD-L1 status groups by central assessment...

Nov 10, 2022 09:00 am ET

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

Nov 09, 2022 08:00 am ET

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345...

Nov 04, 2022 08:00 am ET

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Nov 02, 2022 08:00 am ET

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Nov 01, 2022 07:59 pm ET

Immutep to Participate in Two Upcoming Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO will be presenting at two...

Oct 26, 2022 08:00 am ET

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Oct 25, 2022 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today provides an update on the ongoing development of its product...

Oct 05, 2022 08:00 am ET

Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, will announce first interim data from the INSIGHT-003 clinical trial...

Oct 04, 2022 08:00 am ET

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced the United States Food and Drug Administration (FDA)...

Sep 26, 2022 08:00 am ET

Immutep to Participate in Two Upcoming Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, and Deanne Miller, COO, will...

Sep 23, 2022 08:00 am ET

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

Sep 14, 2022 08:00 am ET

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update for its first-in-class...

Sep 13, 2022 08:00 am ET

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific...

Sep 06, 2022 08:00 am ET

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland to...

Aug 30, 2022 08:00 am ET

Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number...

Aug 01, 2022 08:00 am ET

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from 2nd line NSCLC...

Jul 28, 2022 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product...

Jul 06, 2022 08:00 am ET

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled...

Jun 27, 2022 08:00 am ET

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer...

Jun 03, 2022 02:18 pm ET

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data from 1st line NSCLC patients (Part A) of...

Jun 02, 2022 08:00 am ET

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line...

May 27, 2022 08:00 am ET

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from Part A of the...

May 20, 2022 08:00 am ET

Immutep to Present at Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to present at investor...

May 18, 2022 08:00 am ET

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the...

May 04, 2022 09:31 am ET

Thinking about buying stock in Immutep, Brickell Biotech, Indonesia Energy, TG Therapeutics, or Aquestive Therapeutics?

NEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMP, BBI, INDO, TGTX, and AQST.

May 04, 2022 08:00 am ET

Immutep Presents New and Significant Data from the AIPAC Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis data from...

Apr 29, 2022 08:00 am ET

Immutep Quarterly Activities Report

Apr 28, 2022 08:00 am ET

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from first line non-small cell lung...

Mar 30, 2022 08:00 am ET

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data in 2nd line metastatic NSCLC from...

Mar 24, 2022 08:00 am ET

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line...

Mar 18, 2022 08:00 am ET

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. This new Japanese patent was...

Mar 18, 2022 08:00 am ET

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress 2022, which will take place onsite in Berlin,...

Mar 10, 2022 08:00 am ET

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product...

Feb 24, 2022 08:00 am ET

Immutep to Present at Healthcare Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited present at investor...

Feb 18, 2022 08:00 am ET

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO’s European Lung Cancer Congress (ELCC) 2022 which will take place in-person in Prague, Czech Republic and...

Feb 11, 2022 08:00 am ET

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number...

Jan 31, 2022 08:00 am ET

Immutep to Present at February Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited...

Jan 25, 2022 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product...

Dec 16, 2021 08:00 am ET

Immutep Advances IMP761 Manufacturing

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has signed a Manufacturing Service...

Dec 02, 2021 08:00 am ET

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first five patients have been treated in the...

Nov 19, 2021 08:00 am ET

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the last patient has been enrolled in the expansion...

Nov 15, 2021 08:00 am ET

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL...

Nov 15, 2021 08:00 am ET

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Survival (OS) data from the abstract published on 9 November 2021, including statistically significant benefit in 3 patient subgroups representing a majority...

Nov 09, 2021 08:05 am ET

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

details below SYDNEY, AUSTRALIA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and...

Nov 09, 2021 08:00 am ET

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancerOS benefit trend in total population, with median survival benefit of +2.9 months from efti plus chemotherapy,...

Nov 02, 2021 08:00 am ET

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL...

Oct 29, 2021 08:00 am ET

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it has received positive feedback from...

Oct 28, 2021 08:00 am ET

Immutep Quarterly Activities Report & Appendix 4C

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product...

Oct 01, 2021 08:00 am ET

Immutep to Present Phase II TACTI-002 Data at SITC 2021

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce data from Part C of its ongoing Phase...

Sep 29, 2021 08:00 am ET

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

Sep 28, 2021 08:00 am ET

Immutep to Present at Healthcare Investor Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences, as outlined below....

Sep 21, 2021 08:38 am ET

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will report final Overall Survival...

Sep 01, 2021 08:00 am ET

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

Last 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of Part BTotal of 154 patients out of up to 183 patients (84%) now participating in the expanded...

Aug 31, 2021 08:00 am ET

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti” or “IMP321”), EOC Pharma (“EOC”) is planning to expand its clinical...

Aug 27, 2021 08:00 am ET

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody molecules to LAG-3 and uses thereof” by the Chinese...

Aug 05, 2021 08:00 am ET

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been...

Jul 13, 2021 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product...

Jul 06, 2021 08:00 am ET

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

ASX/Media Release Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003Patient recruitment into the trial is expected to begin within...

Jun 21, 2021 08:00 am ET

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to announce that it has received commitments for a A$60 million two-tranche private placement of new ordinary shares (New Shares) to professional, institutional and...

Jun 21, 2021 08:00 am ET

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces it has signed an agreement to commence a new Phase...

Jun 08, 2021 08:00 am ET

Immutep Reveals a New Anti-LAG-3 Research Program

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline....

Jun 04, 2021 08:00 am ET

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall response rate (ORR) together with favourable duration and depth of responses in 1st line NSCLC (41.7%, 2 CRs; minimum DoR > 6 months) and 2nd line...

Jun 04, 2021 08:00 am ET

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces encouraging final data from its Phase I INSIGHT-004...

Jun 02, 2021 08:00 am ET

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number EP3473263 entitled...

Jun 01, 2021 08:00 am ET

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announces a new collaboration and supply agreement with Merck KGaA ,...

May 26, 2021 08:00 am ET

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL201480073584.3)...

May 25, 2021 08:00 am ET

Immutep To Present At The Jefferies Virtual Healthcare Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate...

May 20, 2021 08:00 am ET

Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its TACTI-002 and...

May 07, 2021 08:00 am ET

Immutep Operational Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and preclinical programs....

Apr 28, 2021 10:21 am ET

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004...

Apr 19, 2021 08:00 am ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates,...

Apr 16, 2021 08:00 am ET

Immutep Receives A$1,155,055 R&D Tax Incentive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of...

Apr 08, 2021 08:00 am ET

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces its lead product candidate eftilagimod alpha...

Apr 07, 2021 08:00 am ET

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number...

Mar 17, 2021 08:00 am ET

Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate...

Mar 16, 2021 08:00 am ET

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer

Mar 09, 2021 08:00 am ET

IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR

Mar 05, 2021 08:00 am ET

Immutep Expands Part B of TACTI-002 Study

– Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s...

Jan 27, 2021 08:00 am ET

Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced that an independent Data and Safety Monitoring Board (DSMB) has...

Jan 21, 2021 06:03 pm ET

Immutep Quarterly Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates,...

Jan 21, 2021 05:40 pm ET

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase...

Jan 06, 2021 07:04 pm ET

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its...

Dec 29, 2020 04:54 pm ET

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Dec 16, 2020 08:00 am ET

Immutep Upscales Efti Manufacturing

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement of the process of scaling up the...

Dec 15, 2020 08:00 am ET

Immutep Operational Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs. Eftilagimod alpha (“efti”)...

Dec 09, 2020 05:52 pm ET

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial...

Dec 09, 2020 05:13 pm ET

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to report encouraging first Overall Survival (OS) follow up data from its ongoing Phase IIb...

Nov 18, 2020 06:19 pm ET

Immutep Announces Expansion of TACTI-002 Collaboration Trial

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial. TACTI-002...

Nov 18, 2020 05:58 pm ET

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully...

Nov 09, 2020 04:10 pm ET

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

ASX/Media Release Overall Response Rates (ORR) in 1st line NSCLC and 2nd line HNSCC continue to be very...

Nov 09, 2020 08:00 am ET

Immutep Announces Australian Patent Grant For IMP701 Antibody

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Patent Office. This new Australian patent builds on...

Nov 02, 2020 05:24 pm ET

Immutep’s TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002...

Oct 29, 2020 08:44 am ET

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with LabCorp that...

Oct 23, 2020 08:00 am ET

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated...

Oct 21, 2020 06:44 pm ET

Immutep Activities Report for the First Quarter of Fiscal Year 2021

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today provided a business update for the quarter ended September 30, 2020, including for the ongoing...

Oct 21, 2020 08:00 am ET

Immutep Granted European Patent for IMP761

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled...

Oct 19, 2020 08:00 am ET

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that interim Overall Survival (OS) results from its...

Sep 17, 2020 08:23 pm ET

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date...

Sep 17, 2020 07:53 pm ET

Immutep Reports Improving Results from INSIGHT-004 Trial

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 on 17 September 2020, CEST (poster ID number 1032P) by...

Aug 31, 2020 08:00 am ET

Immutep and Monash University Receive Grant Funding for LAG-3 Project

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,427 grant under the ARC‘s Linkage Project scheme to support their research...

Aug 26, 2020 08:00 am ET

New Data From Immutep’s efti to be Presented at ESMO

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce new data is scheduled to be presented in four poster...

Aug 18, 2020 08:00 am ET

Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for...

Aug 17, 2020 08:00 am ET

Immutep Issues Newsletter Update to Shareholders

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, issued a newsletter to update its shareholders from Executive Director and...

Aug 11, 2020 08:00 am ET

Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 10,736,940)...

Jul 23, 2020 09:31 am ET

Thinking about buying stock in Entera Bio, Immutep, Electrameccanica Vehicles, Delta Air Lines, or Carnival Corp?

NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, IMMP, SOLO, DAL, and CCL.

Jul 15, 2020 10:45 am ET

Thinking about buying stock in Phunware Inc, American Airlines, General Electric, Genetic Technologies, or Immutep?

NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, AAL, GE, GENE, and IMMP.

Jul 14, 2020 07:00 pm ET

Immutep Announces United States Patent Grant for IMP701 Antibody

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office. This new United States...

Jun 29, 2020 08:00 am ET

Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for...

Jun 22, 2020 08:00 am ET

Immutep receives A$1,437,826 R&D Tax Incentive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of...

May 31, 2020 07:40 pm ET

Immutep Announces Improving Data from the Phase II TACTI-002 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows improving efficacy results. The results were presented as a poster short...

May 31, 2020 07:30 pm ET

Immutep Reports First Results from INSIGHT-004 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha...

May 28, 2020 08:14 pm ET

Immutep Receives US$2.4 Million R&D Tax Incentive from French Government

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ US$2,407,817)...

May 26, 2020 08:13 pm ET

Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT). CEO Marc Voigt, CSO and CMO, Dr Frederic...

Apr 29, 2020 09:12 pm ET

Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two poster presentations during the American Society of Clinical Oncology’s (ASCO) Annual Meeting, a leading...

Apr 28, 2020 08:00 am ET

Immutep Reports Positive Phase II TACTI-002 Data

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002...

Apr 21, 2020 08:17 pm ET

Enrollment completed for the INSIGHT-004 Study

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the...

Apr 15, 2020 09:35 pm ET

Immutep Advances Cell Line Development for IMP761

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress in the cell line development for...

Apr 14, 2020 12:06 am ET

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected...

Apr 08, 2020 08:00 am ET

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing efti (designated as EOC202 in...

Mar 24, 2020 09:35 pm ET

Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announces data from its Phase IIb AIPAC clinical trial in...

Mar 19, 2020 08:02 pm ET

Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the ongoing EOC202A1101 study being conducted in China. EOC...

Mar 09, 2020 08:00 am ET

Immutep Receives Second IND approval for Efti from US FDA

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces the approval of its Investigational New Drug (“IND”) application...

Feb 19, 2020 08:00 am ET

Immutep Reports Positive TACTI-002 Data

Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of 2nd line head and neck squamous cell carcinoma (HNSCC) patientsNSCLC...

Feb 04, 2020 08:00 am ET

Immutep to Present TACTI-002 Interim Data at German Cancer Congress

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that more mature interim TACTI-002 clinical data will be presented...

Jan 29, 2020 08:00 am ET

Immutep Activities Report

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates,...

Jan 09, 2020 08:00 am ET

Immutep Expands Part C of TACTI-002 Due to Positive Data

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on its TACTI-002 and AIPAC studies for its lead product...

Dec 19, 2019 08:00 am ET

INSIGHT-004 Clinical Trial Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the INSIGHT-004 Phase I clinical trial to evaluate...

Nov 14, 2019 08:00 am ET

Immutep Announces European Patent Grant for LAG525 Antibody

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “Antibody molecules to LAG-3 and uses thereof” by the European Patent Office. The claims of the patent are...

Nov 08, 2019 08:00 am ET

Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reports positive interim data from its open label TACTI-002 Phase II...

Oct 28, 2019 08:00 am ET

Operational Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates....

Oct 15, 2019 08:00 am ET

Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase I...

Oct 10, 2019 08:00 am ET

Immutep Announces Data Presentations at Upcoming Industry Conferences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate...

Oct 10, 2019 08:00 am ET

Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

Sep 26, 2019 08:00 am ET

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or the “Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that the requisite number of predefined patient responses has...

Sep 23, 2019 08:00 am ET

Immutep to Receive £4M Milestone Payment From GSK

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it will receive a milestone payment from GSK of £4 million...

Sep 17, 2019 08:00 am ET

Immutep Announces Japanese Patent Grant for LAG525 Antibody

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. The claims of the patent are...

Aug 22, 2019 08:00 am ET

Immutep Granted European Patent for Eftilagimod Alpha in Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2601962) entitled...

Aug 06, 2019 08:00 am ET

Immutep Completes A$6M Entitlement Offer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the completion of its fully underwritten pro rata non-renounceable entitlement offer (“Entitlement Offer”) of new fully paid ordinary shares in Immutep...

Jul 26, 2019 08:00 am ET

Operational Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates as...

Jul 02, 2019 12:00 pm ET

Edison Issues ADR Update On Immutep (IMMP)

LONDON, UK / ACCESSWIRE / July 2, 2019 / Immutep's AIPAC Phase IIb study of its antigen-presenting cell activator eftilagimod alpha (efti) plus chemotherapy in breast cancer is fully recruited and expected to report top-line data in Q120. The initial tranche of 17 subjects in the first-line lung cancer arm of the TACTI-002 study of efti plus Keytruda (in collaboration with US Merck) has completed enrolment; the cohort will be expanded to 36 subjects if more than four responses are observed (we expect initial response rate data in Q419). Enrolment in second-line lung and head a

Jun 25, 2019 08:00 am ET

Ad blocking detected

Immutep Limited - American Depositary Shares (OQ:IMMP)

Business Focus: N/A